Medicine:Josef Smolen

From HandWiki
Short description: Austrian rheumatologist and immunologist (born 1950)


Josef Smolen (born March 24, 1950[1][2]) is an Austrian rheumatologist and immunologist and professor emeritus at the Medical University of Vienna.[3][4] Since 2018, he is chairman emeritus of the Department of Internal Medicine 3 and the Division of Rheumatology at the Medical University of Vienna and Vienna General Hospital[5] and was the chairman of the 2nd Medical Department and Center for Diagnosis and Therapy of Rheumatic Diseases at the Lainz Hospital, now the Hietzing Clinic of the Vienna Health Association from 1989 to 2017.[3]

Biography

Smolen graduated from the Bundesrealgymnasium I Stubenbastei in 1968[6] and then studied medicine at the University of Vienna, where he obtained his doctorate in January 1975.[7][8] From March 1975 to August 1976, he conducted research at the Institute of Immunology at the University of Vienna,[9] and from September 1976 he was a resident at the 2nd Department of Medicine, University of Vienna, where he completed his training in internal medicine and rheumatology.[9] From 1980–1981, he was a research fellow at the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK, now NIAMS) of the National Institutes of Health in Bethesda, MD, USA, with Alfred D. Steinberg.[9][10] He became a senior physician with a leading function at the department's rheumatology unit in 1983.[9]

His habilitation in clinical immunology in 1985 was followed by his habilitation in internal medicine in 1987.[9] In 1989, he was appointed head of the 2nd Medical Department of the Lainz Hospital of the City of Vienna (Center for Diagnostics and Therapy of Rheumatic Diseases), a position he held until the end of 2017.[9][11]

In 1995, he was appointed Professor of Internal Medicine and Head of the Division of Rheumatology at the Department of Medicine 3 of the University of Vienna (later Medical University of Vienna) and Vienna General Hospital[9] and from 2007 also served as Head of the Department of Internal Medicine 3, a position he held until his retirement at the end of September 2018.[12]

Smolen was President of the European League Against Rheumatism (EULAR) from 2003 go 2005.[13] From 1998 to 2001, he was Treasurer of the International Union of Immunological Societies (IUIS).[14] From 2006 to 2008, he was President of the Austrian Society for Allergology and Immunology (ÖGAI)[15][16] and from 2004 to 2006 President of the Austrian Society for Rheumatology and Rehabilitation (ÖGR).[17][18][19]

In 2003, Smolen was elected a corresponding member of the Austrian Academy of Sciences (ÖAW) and in 2005 a full member.[20] In 2007, he was elected a member of the German Academy of Sciences Leopoldina – National Academy of Sciences.[21] Since 2017, Smolen has been Editor-in-Chief of the scientific journal Annals of the Rheumatic Diseases – The EULAR Journal,[22][23] which had an impact factor of over 27 in 2022.[24] Since 2003, he has been one of the authors of the textbook "Rheumatology".[25] Together with Kurt Redlich and Daniel Aletaha, he is the founder of the German-languaged scientific journal "Fakten der Rheumatologie"[26] published by MedMedia Verlag.


Research

Smolen has published more than 700 scientific papers, including in the New England Journal of Medicine, The Lancet, JAMA, Nature Medicine, Annals of the Rheumatic Diseases and Journal of Clinical Investigation, on topics relating to immunology and rheumatology, with his research activities focusing on the pathogenesis and treatment of rheumatic diseases.[27] In this context, together with his many colleagues, he has gained new insights into the development and propagation of joint destruction and helped to develop new therapies for rheumatoid arthritis and other inflammatory rheumatic diseases.[28] The innovative therapies whose development he has significantly influenced include biologics such as monoclonal antibodies against TNF (infliximab, golimumab, certolizumab)[29][30][31] or the IL-6 receptor (tocilizumab)[32] as well as Janus kinase inhibitors (baricitinib, upadacitinib).[33][34] Previously, he made significant contributions to the understanding of other then new drugs, such as leflunomide.[35] Most recently, he was involved in the development of an antibody against IL-6 (olokizumab).[36]

Smolen and his team have developed new disease activity scores for rheumatoid arthritis (Simplified Disease Activity Index, SDAI, and Clinical Disease Activity Index, CDAI),[37][38] psoriatic arthritis (Disease Activity index for PSoriatic Arthritis, DAPSA)[39] and reactive arthritis (Disease Activity index for REactive Arthritis, DAREA),[40] which are used worldwide.[41][42][43] He was also spiritus rector in the development and expansion of the treat-to-target concept (targeted therapy) for rheumatic diseases.[44][45][46][47]

In the course of studies on autologous mixed lymphocyte culture, Smolen, together with Thomas Luger and others, showed for the first time that CD8 lymphocytes produce interleukin-2, a finding that broke through a dogma at the time.[48][49] Together with Günter Steiner and others, he discovered a new autoantigen, RA-33, which triggers an autoimmune response, particularly in rheumatoid arthritis.[50][51] To optimize the treatment of patients with rheumatoid arthritis, Smolen established immediate access early arthritis outpatient clinics at the Hietzing Hospital and the General Hospital[52] herewith developed a concept to reduce waiting times for patients, which has enabled many rheumatoid arthritis patients to receive rapid and efficient help.[52]

He is the author of a series of EULAR recommendations on the treatment of several rheumatic diseases.[53][54][55][56][57] Since almost two decades he is one of the editors of the Textbook "Rheumatology", whose 8th edition has been published recently.[58] Smolen has been one of the Highly Cited Researchers for many years[59][60] and is a much sought-after speaker and teacher at international and national congresses and other events.[61][62]

Honors

  • 2007 Carol Nachman Prize[63]
  • 2007 Golden Key of the City of Cuenca[64]
  • 2008 Fellow of the Royal Society of Medicine (FRCP)[65][66]
  • 2009 Decoration of Honor in Gold for services to the State of Vienna[67]
  • 2010 Doctor honoris causa of the University of Lund (Sweden)[68][69]
  • 2014 Doctor honoris causa of the University of Leiden (Netherlands)[70][71]
  • 2015 Master of the American College of Rheumatology[72]
  • 2017 Doctor honoris causa from Semmelweis University Budapest (Hungary)[73]
  • 2018 Awarded the Golden Town Hall Man by the Mayor of the City of Vienna[7]
  • 2020 Prize of the City of Vienna for Medical Sciences[74]
  • Honorary memberships of the Italian, Polish (2011),[75] Slovakian, Slovenian and German (2019)[76] Societies of Rheumatology and EULAR[77]

Activities in literary studies

In addition to medical research, Smolen is also active in the field of literature, with a focus on literary expressionism. In this regard, he has written four bibliographies, namely one on the series "Der jüngste Tag" by Kurt Wolff Verlag (2nd edition 2013 by Burg-Verlag, Vienna),[78][79] one on the series "Der rote Hahn" by Aktionsverlag (2019),[80] one on the series "Das neuste Gedicht" by Dresdner Verlag of 1917 (2020)[81] and another one on "Lyrische Flugblätter des Alfred Richard Meyer Verlags" (2021),[82][83] all published by Rotes Antiquariat, Vienna-Berlin.[84] thumb

Most recently, a work focusing on Vienna at the turn of the century was published: "Fritzi Löw und die Buchkunst in Wien um 1900 – Neuentdeckes zu Kunstschaffenden und Verlagen", covering book-art in Vienna at the beginning of the 20th century,[85][86] and was presented at the Museum of Applied Arts in Vienna in 2023.[85] thumb

References

  1. ↑ "Josef S Smolen". https://www.wikidata.org/wiki/Q66753681. 
  2. ↑ "Curriculum Vitae Prof. Dr. Josef Smolen". https://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV_Josef_Smolen_D.pdf. 
  3. ↑ 3.0 3.1 "Invited Faculty - Josef S. Smolen". https://www.lupus-kcr2023.org/program/inv_modal.html?cv_code=MjAyMzAwMDAwMDEwMTRfMDAwMDE2. 
  4. ↑ "Meet the Speakers: ORA 19th Annual Scientific Meeting – Ontario Rheumatology Association". https://ontariorheum.ca/meet-the-speakers-ora-2019-annual-scientific-meeting/meet-the-speakers-ora-19th-annual-scientific-meeting. 
  5. ↑ Wien, Medizinischen Universität. "Events | MedUni Wien". https://www.meduniwien.ac.at/web/ueber-uns/events/detail/. 
  6. ↑ "Absolvent:innen | GRG 1 Stubenbastei". https://www.stubenbastei.at/absolventinnen. 
  7. ↑ 7.0 7.1 Vienna, Medical University of. "Josef Smolen awarded". https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2018/news-jaenner-2018/josef-smolen-awarded-goldener-rathausmann/. 
  8. ↑ "Prof. Josef Smolen". https://emeunet.eular.org/myUploadData/files/Josef_Smolen_CV.pdf. 
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 "Mitglieder". https://www.leopoldina.org/mitgliederverzeichnis/mitglieder/member/Member/show/josef-smolen/. 
  10. ↑ "Josef Smolen | ScienceBlog". https://scienceblog.at/josef-smolen. 
  11. ↑ ""Ein offener Dialog ist mir wichtig"". https://www.universimed.com/at/article/rheumatologie/ein-offener-dialog-ist-mir-wichtig-2108223#!. 
  12. ↑ "Prim. Univ.-Prof. Dr. med. Dr. h. c. mult. Josef Smolen". https://www.wien.gv.at/video/3406/Prim-Univ-Prof-Dr-med-Dr-h-c-mult-Josef-Smolen. 
  13. ↑ "EULAR Presidents". https://www.eular.org/eular-presidents. 
  14. ↑ "Page 1". https://contentdm.ad.umbc.edu/digital/collection/IUIS/id/545. 
  15. ↑ "Österreichischen Gesellschaft für Allergologe und Immunologie, Happy 50th Birthday!" (in de). https://oegai.org/wp-content/uploads/2021/04/Geschichte-der-O%CC%88GAI-28.4.2021.pdf. 
  16. ↑ "Österreichische Gesellschaft für Allergologie und Immunologie". October 10, 2023. https://de.wikipedia.org/w/index.php?title=%C3%96sterreichische_Gesellschaft_f%C3%BCr_Allergologie_und_Immunologie&oldid=238033328. 
  17. ↑ "Wer wir sind". https://rheumatologie.at/gesellschaft/wer-wir-sind. 
  18. ↑ "Highlights vom EULAR 2006 - Spitzenleistungen österreichischer Rheumatologen". https://www.ots.at/presseaussendung/OTS_20060626_OTS0044/highlights-vom-eular-2006-spitzenleistungen-oesterreichischer-rheumatologen. 
  19. ↑ "Archivmeldung: "Rheuma-Zelt" startet in Wien". July 13, 2006. https://presse.wien.gv.at/presse/2006/07/13/rheuma-zelt-startet-in-wien. 
  20. ↑ "Josef Smolen". https://www.oeaw.ac.at/en/m/smolen-josef. 
  21. ↑ "List of Members". https://www.leopoldina.org/en/members/list-of-members/list-of-members/member/Member/show/josef-smolen/. 
  22. ↑ "EULAR Journal". https://www.eular.org/eular-journal. 
  23. ↑ "Meet the new Editor in Chief of ARD, Josef Smolen". 28 March 2022. https://www.youtube.com/watch?v=cVfTandqiF8. 
  24. ↑ "Annals of the Rheumatic Diseases". July 19, 2023. https://en.wikipedia.org/w/index.php?title=Annals_of_the_Rheumatic_Diseases&oldid=1166139762. 
  25. ↑ Deighton, C. (2004). "RHEUMATOLOGY, 3rd edition. By M. C. Hochberg, A. J. Silman, J. S. Smolen, M. E. Weinblatt and M. H. Weisman. 225.00. Mosby, 2003. 2282 pages. ISBN 0-323024-04-1". Rheumatology 43 (6): 815–816. doi:10.1093/rheumatology/keh180. https://academic.oup.com/rheumatology/article/43/6/815/1784697. 
  26. ↑ "Fakten der Rheumatologie | MedMedia". https://www.medmedia.at/fdr_ausgaben/fakten-rheumatologie-012023/. 
  27. ↑ "Smolen JS - Search Results - PubMed". https://pubmed.ncbi.nlm.nih.gov/?term=Smolen+JS&size=100. 
  28. ↑ "European Beacon for Rheumatology". https://www.the-rheumatologist.org/article/european-beacon-for-rheumatology/. 
  29. ↑ Smolen, J. S.; Han, C.; Bala, M.; Maini, R. N.; Kalden, J. R.; van der Heijde, D.; Breedveld, F. C.; Furst, D. E. et al. (April 2005). "Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study". Arthritis & Rheumatism 52 (4): 1020–1030. doi:10.1002/art.20982. PMID 15818697. [non-primary source needed]
  30. ↑ Smolen, Josef S; Kay, Jonathan; Doyle, Mittie K; Landewé, Robert; Matteson, Eric L; Wollenhaupt, Jürgen; Gaylis, Norman; Murphy, Frederick T et al. (July 2009). "Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial". The Lancet 374 (9685): 210–221. doi:10.1016/S0140-6736(09)60506-7. PMID 19560810. [non-primary source needed]
  31. ↑ Smolen, J; Landewé, R B; Mease, P; Brzezicki, J; Mason, D; Luijtens, K; van Vollenhoven, R F; Kavanaugh, A et al. (June 2009). "Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial". Annals of the Rheumatic Diseases 68 (6): 797–804. doi:10.1136/ard.2008.101659. PMID 19015207. [non-primary source needed]
  32. ↑ Smolen, Josef S; Beaulieu, Andre; Rubbert-Roth, Andrea; Ramos-Remus, Cesar; Rovensky, Josef; Alecock, Emma; Woodworth, Thasia; Alten, Rieke (March 2008). "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial". The Lancet 371 (9617): 987–997. doi:10.1016/S0140-6736(08)60453-5. PMID 18358926. [non-primary source needed]
  33. ↑ Smolen, Josef S.; Genovese, Mark C.; Takeuchi, Tsutomu; Hyslop, David L.; Macias, William L.; Rooney, Terence; Chen, Lei; Dickson, Christina L. et al. (January 2019). "Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment". The Journal of Rheumatology 46 (1): 7–18. doi:10.3899/jrheum.171361. PMID 30219772. [non-primary source needed]
  34. ↑ Smolen, Josef S; Pangan, Aileen L; Emery, Paul; Rigby, William; Tanaka, Yoshiya; Vargas, Juan Ignacio; Zhang, Ying; Damjanov, Nemanja et al. (June 2019). "Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study". The Lancet 393 (10188): 2303–2311. doi:10.1016/S0140-6736(19)30419-2. PMID 31130260. [non-primary source needed]
  35. ↑ Smolen, Josef S; Kalden, Joachim R; Scott, David L; Rozman, Blaz; Kvien, Tore K; Larsen, Arvi; Loew-Friedrich, Iris; Oed, Christine et al. (January 1999). "Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial". The Lancet 353 (9149): 259–266. doi:10.1016/S0140-6736(98)09403-3. PMID 9929017. [non-primary source needed]
  36. ↑ Smolen, Josef S.; Feist, Eugen; Fatenejad, Saeed; Grishin, Sergey A.; Korneva, Elena V.; Nasonov, Evgeniy L.; Samsonov, Mikhail Y.; Fleischmann, Roy M. (25 August 2022). "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis". New England Journal of Medicine 387 (8): 715–726. doi:10.1056/NEJMoa2201302. PMID 36001712. [non-primary source needed]
  37. ↑ Aletaha, Daniel; Wang, Xin; Zhong, Sheng; Florentinus, Stefan; Monastiriakos, Kelly; Smolen, Josef S. (April 2020). "Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission". Seminars in Arthritis and Rheumatism 50 (2): 276–284. doi:10.1016/j.semarthrit.2019.09.005. PMID 31590930. [non-primary source needed]
  38. ↑ Smolen, JS; Aletaha, D (September 2014). "Scores for all seasons: SDAI and CDAI.". Clinical and Experimental Rheumatology 32 (5 Suppl 85): S-75-9. PMID 25365093. http://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=25365093. [non-primary source needed]
  39. ↑ Smolen, JS; Schoels, M; Aletaha, D (September 2015). "Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review.". Clinical and Experimental Rheumatology 33 (5 Suppl 93): S48-50. PMID 26471734. http://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=26471734. [non-primary source needed]
  40. ↑ Schoels, Monika; Aletaha, Daniel; Funovits, Julia; Kavanaugh, Arthur; Baker, Daniel; Smolen, Josef S (August 2010). "Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis". Annals of the Rheumatic Diseases 69 (8): 1441–1447. doi:10.1136/ard.2009.122259. PMID 20525844. [non-primary source needed]
  41. ↑ Aletaha, D.; Smolen, J. (March 11, 2005). "The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis". Clinical and Experimental Rheumatology 23 (5 Suppl 39): S100–108. PMID 16273793. [non-primary source needed]
  42. ↑ Haugeberg, G.; Michelsen, B.; Tengesdal, S.; Hansen, I. J.; Diamantopoulos, A.; Kavanaugh, A. (2018). "Ten years of follow-up data in psoriatic arthritis: Results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway". Arthritis Research & Therapy 20 (1): 160. doi:10.1186/s13075-018-1659-z. PMID 30071892. 
  43. ↑ Coates, L. C.; Merola, J. F.; Mease, P. J.; Ogdie, A.; Gladman, D. D.; Strand, V.; Van Mens, L. J.; Liu, L. et al. (2020). "Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis". Rheumatology 60 (3): 1137–1147. doi:10.1093/rheumatology/keaa271. PMID 32864685. 
  44. ↑ Smolen, J. S.; Aletaha, D.; Bijlsma, J. W. J.; Breedveld, F. C.; Boumpas, D.; Burmester, G.; Combe, B.; Cutolo, M. et al. (April 11, 2010). "Treating rheumatoid arthritis to target: recommendations of an international task force". Annals of the Rheumatic Diseases 69 (4): 631–637. doi:10.1136/ard.2009.123919. PMID 20215140. [non-primary source needed]
  45. ↑ Smolen, Josef S. (November 2019). "Treat to Target in Rheumatology". Rheumatic Disease Clinics of North America 45 (4): 477–485. doi:10.1016/j.rdc.2019.07.001. PMID 31564291. [non-primary source needed]
  46. ↑ Smolen, Josef S; Aletaha, Daniel; Bijlsma, Johannes W J; Breedveld, Ferdinand C; Boumpas, Dimitrios; Burmester, Gerd; Combe, Bernard; Cutolo, Maurizio et al. (May 2010). "Treating rheumatoid arthritis to target: recommendations of an international task force". Annals of the Rheumatic Diseases 69 (4): 631–637. doi:10.1136/ard.2009.123919. PMID 20215140. [non-primary source needed]
  47. ↑ Smolen, Josef S; Breedveld, Ferdinand C; Burmester, Gerd R; Bykerk, Vivian; Dougados, Maxime; Emery, Paul; Kvien, Tore K; Navarro-Compán, M Victoria et al. (January 2016). "Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force". Annals of the Rheumatic Diseases 75 (1): 3–15. doi:10.1136/annrheumdis-2015-207524. PMID 25969430. [non-primary source needed]
  48. ↑ Luger, T. A.; Smolen, J. S.; Chused, T. M.; Steinberg, A. D.; Oppenheim, J. J. (August 1, 1982). "Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture.". The Journal of Clinical Investigation 70 (2): 470–473. doi:10.1172/JCI110637. PMID 6808028. [non-primary source needed]
  49. ↑ Stingl, L. A.; Sinska, A.; Landesmann, U.; Smolen, J. S. (1987). "Induction of interleukin 2 receptiveness and proliferation in resting peripheral T cells by monoclonal anti-CD3 (T3) antibodies does not require the presence of macrophages". Clinical and Experimental Immunology 68 (1): 146–155. PMID 3115639. [non-primary source needed]
  50. ↑ Steiner, Günter; Smolen, Josef S. (1 December 2002). "Neue Autoantikörper in der Diagnostik der rheumatoiden Arthritis". Zeitschrift für Rheumatologie 61 (6): 667–673. doi:10.1007/s00393-002-0470-y. PMID 12491130. [non-primary source needed]
  51. ↑ Hayer, Silvia; Tohidast-Akrad, Makiyeh; Haralambous, Silva; Jahn-Schmid, Beatrice; Skriner, Karl; Trembleau, Sylvie; Dumortier, Hélène; Pinol-Roma, Serafin et al. (2005). "Aberrant Expression of the Autoantigen Heterogeneous Nuclear Ribonucleoprotein-A2 (RA33) and Spontaneous Formation of Rheumatoid Arthritis-Associated Anti-RA33 Autoantibodies in TNF-α Transgenic Mice". The Journal of Immunology 175 (12): 8327–8336. doi:10.4049/jimmunol.175.12.8327. PMID 16339574. https://journals.aai.org/jimmunol/article/175/12/8327/73166/Aberrant-Expression-of-the-Autoantigen. [non-primary source needed]
  52. ↑ 52.0 52.1 Gärtner, Miriam; Fabrizii, Julia P; Koban, Elisabeth; Holbik, Martin; Machold, Lorenz P; Smolen, Josef S; Machold, Klaus P (March 2012). "Immediate access rheumatology clinic: efficiency and outcomes". Annals of the Rheumatic Diseases 71 (3): 363–368. doi:10.1136/annrheumdis-2011-200315. PMID 21989539. [non-primary source needed]
  53. ↑ Smolen, Josef S; Landewé, Robert B M; Bergstra, Sytske Anne; Kerschbaumer, Andreas; Sepriano, Alexandre; Aletaha, Daniel; Caporali, Roberto; Edwards, Christopher John et al. (January 2023). "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update". Annals of the Rheumatic Diseases 82 (1): 3–18. doi:10.1136/ard-2022-223356. PMID 36357155. [non-primary source needed]
  54. ↑ Smolen, Josef S; Landewé, Robert B M; Bijlsma, Johannes W J; Burmester, Gerd R; Dougados, Maxime; Kerschbaumer, Andreas; McInnes, Iain B; Sepriano, Alexandre et al. (June 2020). "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update". Annals of the Rheumatic Diseases 79 (6): 685–699. doi:10.1136/annrheumdis-2019-216655. PMID 31969328. [non-primary source needed]
  55. ↑ Smolen, Josef S; Landewé, Robert; Bijlsma, Johannes; Burmester, Gerd; Chatzidionysiou, Katerina; Dougados, Maxime; Nam, Jackie; Ramiro, Sofia et al. (June 2017). "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update". Annals of the Rheumatic Diseases 76 (6): 960–977. doi:10.1136/annrheumdis-2016-210715. PMID 28264816. [non-primary source needed]
  56. ↑ Smolen, Josef S; Landewé, Robert; Breedveld, Ferdinand C; Buch, Maya; Burmester, Gerd; Dougados, Maxime; Emery, Paul; Gaujoux-Viala, Cécile et al. (March 2014). "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update". Annals of the Rheumatic Diseases 73 (3): 492–509. doi:10.1136/annrheumdis-2013-204573. PMID 24161836. [non-primary source needed]
  57. ↑ Smolen, Josef S; Landewé, Robert; Breedveld, Ferdinand C; Dougados, Maxime; Emery, Paul; Gaujoux-Viala, Cecile; Gorter, Simone; Knevel, Rachel et al. (June 2010). "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs". Annals of the Rheumatic Diseases 69 (6): 964–975. doi:10.1136/ard.2009.126532. PMID 20444750. [non-primary source needed]
  58. ↑ "Rheumatology, 2-Volume Set - 9780702081330". https://www.us.elsevierhealth.com/rheumatology-2-volume-set-9780702081330.html. 
  59. ↑ "Highly Cited Researchers". 13 November 2024. https://publons.com/wos-op/awards/highly-cited/2020/. 
  60. ↑ red, science ORF at/Agenturen (November 18, 2020). "Österreichs meistzitierte Forscher und Forscherinnen". https://science.orf.at/stories/3203017/. 
  61. ↑ "Meet the Speakers: ORA 20th Annual Scientific Meeting – Ontario Rheumatology Association". https://ontariorheum.ca/meet-the-speakers-ora-2019-annual-scientific-meeting. 
  62. ↑ "Prof. Josef SMOLEN < 21st SSR-MSR Virtual Workshops in Rheumatology". https://ssr-msr2021.com/faculty/prof-josef-smolen/. 
  63. ↑ "rheuma-online.at: Carol-Nachman-Preis für Jane Salmon und Josef Smolen". https://www.rheuma-online.at/fuer-oesterreich/rheuma-news-austria/artikel/carol-nachman-preis-fuer-jane-salmon/. 
  64. ↑ "3. Conocimiento y resolución sobre la petición formulada por los Señores Concejales: Dra. Flor María Salazar y Dr. Gustavo Vega; relacionado con la entrega de las Llaves de la Ciudad al Dr. JOSEF S. SMOLEN. | GAD Municipal de Cuenca". https://www.cuenca.gob.ec/node/5745. 
  65. ↑ "EULAR Meritorious Service Awards 2021". https://www.eurekalert.org/news-releases/679412. 
  66. ↑ "Eular meritorious service awards 2021: professor Maxime Dougados and professor Josef Smolen named recipients". https://web01.adot.ch/sysModules/obxContent/files/www.eular.2015/1_42291DEB-50E5-49AE-5726D0FAAA83A7D4/press_release_eular_2021_meritorious_service_awards_(1).pdf. 
  67. ↑ "Archivmeldung: RK-Terminvorschau vom 16.11. bis 7.12. 2009". November 12, 2009. https://presse.wien.gv.at/presse/2009/11/12/rk-terminvorschau-vom-16-11-bis-7-12-2009. 
  68. ↑ "Nya hedersdoktorer" (in sv). p. 39. https://www.lu.se/sites/www.lu.se/files/lunds-universitets-magasin-2-2010.pdf. 
  69. ↑ "246 nya doktorer pryds med hatt och krans". May 26, 2010. https://www.mynewsdesk.com/se/lu/pressreleases/246-nya-doktorer-pryds-med-hatt-och-krans-414857. 
  70. ↑ "Honorary doctorates and prizes". https://www.universiteitleiden.nl/en/about-us/facts-and-figures/laureates. 
  71. ↑ "Dies natalis 2014 of the Universiteit Leiden". January 3, 2014. https://diplomatmagazine.eu/2014/01/03/dies-natalis-2014-universiteit-leiden/. 
  72. ↑ "2015 ACR Masters". November 6, 2015. https://www.acrconvergencetoday.org/2015-acr-masters/. 
  73. ↑ "Eight professors have received the Doctor Honoris Causa Award of Semmelweis University". November 17, 2017. https://semmelweis.hu/english/2017/11/eight-professors-have-received-the-doctor-honoris-causa-award-of-semmelweis-university/. 
  74. ↑ Vienna, Medical University of. "City of Vienna prizes awarded to members of MedUni Vienna | MedUni Vienna". https://www.meduniwien.ac.at/web/en/ueber-uns/news/news-im-mai-2022/preise-der-stadt-wien-an-mitglieder-der-meduni-wien/. 
  75. ↑ "Członkowie honorowi PTR - Polskie Towarzystwo Reumatologiczne". https://reumatologia.ptr.net.pl/. 
  76. ↑ "Deutsche Gesellschaft für Rheumatologie e.V.". https://dgrh.de/Start/DGRh/Mitgliedschaft/Ehrenmitglieder/Josef-Smolen-und-Dieter-Mitrenga-zu-Ehrenmitgliedern-ernannt.html. 
  77. ↑ "Awards Honorary Members". https://www.eular.org/awards-honorary-members. 
  78. ↑ "Verband der Antiquare Österreichs - Gemeinschaftskatalog" (in de). https://www.pirckheimer.org/docs/BUCHWIEN_2015.pdf. 
  79. ↑ Der Jüngste Tag: Eine neue Bibliographie. -. https://antiquarisch.de/giaq/article/39778636-smolen-josef-der-jngste-tag-eine-neue. 
  80. ↑ "Rotes Antiquariat". https://www.rotes-antiquariat.de/index.php?action=books_detail&proid=215630. 
  81. ↑ "Rotes Antiquariat". https://www.rotes-antiquariat.de/index.php?action=books_detail&proid=215026. 
  82. ↑ Lyrische Flugblätter. March 11, 1907. https://katalog.slub-dresden.de/en/id/0-1830317105. 
  83. ↑ "Mitglied der Pirckheimer-Gesellschaft | Pirckheimer-Gesellschaft". https://pirckheimer-gesellschaft.org/blog/mitglied-der-pirckheimer-gesellschaft. 
  84. ↑ "Rotes Antiquariat". https://www.rotes-antiquariat.de/. 
  85. ↑ 85.0 85.1 "Veranstaltung - MAK Museum Wien". https://www.mak.at/veranstaltung/buchpraesentation_fritzi_loew_und_die_buchkunst_in_wien_um_1900. 
  86. ↑ Holzer, Konrad. "FRITZI LÖW UND DIE WIENER BUCHKUNST – Flaneurin". https://www.flaneurin.at/fritzi-loew-und-die-wiener-buchkunst/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Josef_Smolen&oldid=4017111"